Work

Shared type 2 inflammation, divergent organ responses: mechanisms and therapeutic implications of biologics across atopic dermatitis, asthma, and eosinophilic esophagitis

Year: 2026
Type: article
Abstract: Atopic dermatitis (AD), asthma, and eosinophilic esophagitis (EoE) are distinct inflammatory diseases of the skin, airways, and esophagus, respectively. These disorders can coexist and share overlapping immune pathways, but their manifestations and treatment responses differ substantially across organs. In this narrative review, we examine how differences in epithelial biology, structural cells, neural regulation, tissue remodeling, and injury patterns shape shared type 2 inflammation in each organ. We review clinical evidence for biologics targeting interleukin-4 receptor alpha (IL-4Rα), interleukin-13 (IL-13), interleukin-5 (IL-5) or its receptor alpha subunit (IL-5Rα), immunoglobulin E (IgE), and thymic stromal lymphopoietin (TSLP) across AD, asthma, and EoE. Particular attention is given to discordance between changes in biomarkers or tissue inflammation and improvements in symptoms or organ function. We also consider how current disease activity, pre-existing structural damage, drug exposure, and disease-specific outcome measures affect the assessment of treatment in patients with multimorbidity. Most cross-disease inferences still rely on separate single-disease trials, and prospective studies of patients with active involvement of multiple organs remain scarce. By critically integrating positive, negative, and discordant clinical trial findings, this review distinguishes disease-specific efficacy from direct evidence of concurrent multi-organ benefit. We examine how pathway dependence, tissue pathology, drug exposure, and methodological differences may contribute to discordance among biological, symptomatic, and functional outcomes. This synthesis provides an interpretive framework for assessing the applicability and limitations of existing evidence to patients with type 2 inflammatory multimorbidity and identifies priorities for future prospective studies.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236260628
FWCI:
Cites: 95
Cited by:
Related to: 10
Parts: 1